Browse Articles

Discover research articles across all indexed journals

Neuropathy, skin rash, and hyperglycemia as predictors of response to enfortumab vedotin in locally advanced and metastatic bladder and upper tract urothelial carcinoma.

Journal of Clinical Oncology Tareq Salous, Rebecca Hassoun, Sandra K. Althouse et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.771

771 Background: Enfortumab vedotin (EV) in combination with pembrolizumab is FDA approved for treatment of locally advanced and metastatic urothelial cancer. Neuropathy, skin rash, and hyperglycemia are common side effects of EV. We evaluated the impact of presence of neuropathy, skin rash, and hyperglycemia on progression free survival (PFS) in patients (pts) with bladder or upper tract urothelial carcinoma treated with EV. Methods: The Indiana University bladder cancer database was queried for pts with locally advanced and metastatic bladder and upper tract urothelial carcinoma who were treated with EV with or without pembrolizumab. Pts with variant histology were included. Toxicities were documented throughout the course of treatment. Association of neuropathy, skin rash and hyperglycemia and PFS were compared to patients without any of the side effects using the log-rank test. Results: Between 2018-2024, a total of 83 pts were treated with EV with at least 2 doses. The median age was 69 years (range, 39-89). 47 pts had EV + pembrolizumab, while 36 pts had EV as single agent. 43 pts received EV as 1st, 28 pts as 2nd, 10 pts as 3rd, and 2 pts as 4th line of treatment. Metastatic sites were lymph nodes in 42 pts, lungs in 34 pts, bones in 29 pts, liver in 16 pts, and brain in 7 pts. Median follow-up from the start of EV treatment was 14 months (range, 1-33). Neuropathy was reported in 30 (36%) pts, skin rash in 32 (39%) pts, and hyperglycemia in 6 (7%) pts. The median PFS in patients who did not experience neuropathy/skin rash/hyperglycemia was 4.5 months (95% CI, 2.4-11.0), 10.6 months (95% CI, 7.2-15.7) in pts who experienced neuropathy (P = 0,01), 8.6 months (95% CI, 7.3-20.2) in pts who experienced skin rash (P = 0.01), and 15.9 months (95% CI, 5.1-15.9) in pts who experienced hyperglycemia (P = 0.03). Conclusions: The presence of neuropathy, skin rash, or hyperglycemia in patients with metastatic bladder or upper tract urothelial carcinoma treated with EV was associated with improved PFS.

Phase 2 study of perioperative lenvatinib (L) with pembrolizumab (P) in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.

Journal of Clinical Oncology Mehmet Asim Bilen, Yuan Liu, Amir Davarpanahfakhr et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.555

555 Background: L is an oral multi-kinase inhibitor targeting vascular endothelial growth factor receptors 1-3, fibroblast growth factor receptors 1-4, platelet-derived growth factor receptor α, RET, and KIT. P is a potent humanized immunoglobulin G4 monoclonal antibody with high specificity for binding to the programmed cell death 1 receptor. The combination of P+L was approved for the treatment of advanced renal cell carcinoma (RCC). The enhanced response rates in metastatic RCC with this combination, along with emerging neoadjuvant data, support its potential use in the neoadjuvant setting. Methods: Patients with biopsy-confirmed clear cell RCC of clinical stage ≥ T3Nx, TanyN+, or those deemed unresectable by an experienced surgical team were eligible for this study. They received 4 cycles of P+L (starting dose: 20 mg daily) over 12 weeks, followed by surgery and 13 cycles of adjuvant P monotherapy. The primary endpoint was the objective response rate (ORR) at week 12, assessed per RECIST v1.1 by independent radiological review, including complete and partial responses. Secondary endpoints included safety, tolerability, disease-free survival (DFS), overall survival (OS), surgical outcomes, and quality of life. Results: At the time of analysis, 2 patients were still receiving neoadjuvant treatment. Of the 15 patients who completed the 12-week neoadjuvant regimen, 14 (93%) proceeded to surgery as planned without delay following a minimum 7-day washout period. One patient is awaiting surgery. One patient was not evaluable due to incomplete neoadjuvant treatment caused by concurrent immune-related adverse events (irAEs) rhabdomyolysis and hepatitis (grade 4), though surgery was performed after irAE management. Among evaluable patients, 3/15 (20%) exhibited a partial response, while 12/15 (80%) had stable disease. No patients experienced disease progression while on pembrolizumab+lenvatinib. The median reduction in primary renal tumor size was 21% (range: 3-37%).The most common adverse events (AEs) were fatigue (n=14), palmar-plantar erythrodysesthesia syndrome (n=9), hypertension (n=8), mucositis (n=8), and proteinuria (n=8). Intraoperative complications were not observed, and no postoperative complications related to the drug were noted. No other treatment related grade 4or 5 AEs related to lenvatinib or surgery occurred except for the unevaluable participant. At the time of analysis, two patients had disease recurrence, and one patient had died due to disease progression. Conclusions: The combination of P+L demonstrated clinical activity and a favorable safety profile in the perioperative setting for patients with locally advanced, non-metastatic clear cell RCC. Further data, including long-term outcomes, correlative studies, quality of life assessments, and frailty/sarcopenia indices, will be reported (NCT04393350). Clinical trial information: NCT04393350 .

Study of JAK inhibition in stem-like prostate cancer (JASPER): A phase 1/2 multicenter study of ruxolitinib and enzalutamide in castration resistant prostate cancer undergoing lineage plasticity.

Journal of Clinical Oncology Thomas Christopher Westbrook, Frank Cameron Cackowski, Joshi J. Alumkal et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps297

TPS297 Background: Lineage plasticity (LP) is an increasingly recognized route of resistance in advanced metastatic prostate cancer, and present in approximately 35% of patients at time of death. LP is a continuum of disease states from adenocarcinoma driven by androgen receptor (AR) to AR-independent double negative prostate cancer (DNPC) and neuroendocrine prostate cancer (NEPC). LP has been associated with significantly decreased overall survival compared to other modes of resistance in castration resistant prostate cancer (CRPC). LP can be defined using a combination of molecular and clinical features, but treatment remains imprecise with doublet chemotherapy. Preclinical studies of LP evolution point toward JAK/STAT signaling as important to the process of early lineage plasticity. Furthermore, JAK inhibition combined with AR pathway inhibitor, enzalutamide (enza), was shown to sensitize enza resistant LP models to enza. Genomic studies of patient samples have similarly found JAK/STAT pathway upregulation in tumors which undergo lineage plasticity to DNPC. JAK inhibition in combination with enza may be a promising therapy for prostate cancer at risk or undergoing LP. Methods: JASPER is a phase1/2, multi-center study to evaluate the safety, tolerability, antitumor activity, and pharmacology of ruxolitinib (rux, a JAK inhibitor) combined with enza (160 mg per day) in patients with metastatic CRPC with poor response to prior abiraterone treatment. Poor response is defined as progression within 12 months of starting therapy within hormone-naïve prostate cancer or within 6 months of starting it within CRPC. In the dose escalation phase, a unique pharmacology approach is employed to understand enza’s CYP3A4 induction. A single dose of rux determines intrapatient pharmacokinetics. One week later, the combination starts and the plasma rux values correlated. The pharmacodynamic biomarker phospho-STAT3 in leukocytes will be measured by ELISA. A Bayesian Optimal Interval (BOIN) design determines the maximum tolerated dose (MTD) of rux with enza for the expansion cohort. The expansion cohort has a Simon’s 2 phase design with a 40% response rate goal (3 responses required out of first 13 patients at MTD, total of 39 maximum). The primary endpoint is the MTD of the combination based on rate of drug-related grade 3-5 adverse events experienced within the first 4 weeks of study treatment. Secondary endpoints are a) disease response rate within 6 months of combination therapy start defined by PSA50 decline and/or RECIST 1.1 criteria of partial response or complete response and b) progression free survival defined by Prostate Cancer Working Group 3 criteria. Enrollment is open. Clinical trial information: NCT06616155 .

Chromosome-level genomes of two Bracteacoccaceae highlight adaptations to biocrusts

Nature Communications Hongping Liang, Yan Xu, Sunil Kumar Sahu et al. Feb 10, 2025 DOI: 10.1038/s41467-025-56614-2

Efficacy and safety of fruquintinib combined with serplulimab as 1 <sup>st</sup> line treatment in metastatic or unresectable non-clear cell renal cell carcinoma (nccRCC): Updated results from a single-arm, multicentre clinical trial.

Journal of Clinical Oncology Jiwei Huang, Xiaoyi Hu, Hang Wang et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.542

542 Background: For advanced non-clear cell renal cell carcinoma (nccRCC), systemic therapy is the main option but the treatment standard remains unclear. In the past decade, promising results have emerged from clinical trials with vascular endothelial growth factor receptor (VEGFR) inhibitors, or anti-programmed death-1 (PD-1) antibodies. Fruquintinib (FRU) is a potent VEGFR inhibitor approved for metastatic colorectal cancer. This trial aims to evaluate the efficacy and safety of FRU combined with serplulimab (an anti-PD-1 antibody) in patients (pts) with advanced nccRCC. Methods: This is a multicentre single-arm prospective trial planning to enroll 39 pts with pathologically confirmed metastatic or unresectable nccRCC. Eligible patients were 18 to 80 years old with an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1, and had not received prior systemic therapy. All pts received FRU (5mg, qd, po, 2w on/1w off) plus serplulimab (4.5mg/kg, d1, i.v.gtt, q3w). The primary endpoint was progression-free survival (PFS), and the secondary endpoints included objective response rate (ORR), disease control rate (DCR), safety, etc. Results: As of Sep.20 th , 2024, 16 nccRCC pts were enrolled. The median age was 63.5 years (range 24-78) and 75.0% were male. Seven (43.8%) pts had an ECOG PS of 2. Histologically, papillary subtype was the most prevalent (12, 75.0%), followed by chromophobe (2, 12.5%), 1 collecting duct carcinoma and 1 unclassified subtype, and sarcomatoid features were observed in 5 (31.3%) patients. The metastatic sites were primarily lymph nodes (56.3%), lungs (37.5%), peritoneum (25.0%) and abdominal cavity (25.0%). Among the 16 evaluable pts, 8 achieved partial response and 6 had stable disease, resulting in an ORR of 50.0% (95% CI: 25.5%-74.5%) and a DCR of 87.5% (95% CI: 61.7%-98.4%). Three pts experienced rapid progression, all with sarcomatoid features (2 papillary, 1 chromophobe). The median PFS was not reached. The most common treatment-related adverse events (TRAEs) were rash (37.5%), fever (31.3%), ALT increased (25.0%), AST increased (25.0%), hypertension (18.8%), hypothyroidism (18.8%), fatigue (18.8%) and most were grade 1/2 except 1 pt experiencing grade 3 AST increased. Conclusions: The preliminary data showed promising efficacy and tolerable toxicity of FRU combined with serplulimab in pts with metastatic or unresectable nccRCC. Clinical trial information: NCT05831891 .

Dose finding study of CBM588 in combination with nivolumab and ipilimumab in patients with metastatic renal cell carcinoma: A phase I study.

Journal of Clinical Oncology Ruchi Agarwal, Hedyeh Ebrahimi, Zeynep Busra Zengin et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps611

TPS611 Background: The combination of nivolumab and ipilimumab is currently one of the standard-of-care treatments for patients with metastatic renal cell carcinoma (mRCC). However, in the vast majority of patients, disease progression eventually occurs. Thus, novel methods to increase the efficacy of nivolumab/ipilimumab are being explored. Recent evidence suggests that the gut microbiome can remarkably influence the efficacy of immune checkpoint inhibitors (ICI) in patients with mRCC, particularly through the modulation of microbial diversity and the presence of key bacterial species (Routy et al . Science 2018; Salgia et al . Eur Urol 2020). The current study explores the use of CBM588, Clostridium butyricum MIYARI588, which has demonstrated the potential to enhance clinical outcomes when combined with ICI therapy (Dizman et al . Nature Medicine 2022; Ebrahimi et al . Nature Medicine 2024). This ongoing phase I study aims to determine the maximum tolerated dose (MTD) of CBM588 in combination with nivolumab/ipilimumab in previously untreated mRCC patients, and to evaluate the biological effects of CBM588. Methods: This investigator-initiated, phase I, open-label, single-arm, dose-escalation study is being conducted in patients with untreated, histologically confirmed mRCC. Eligible patients must be ≥18 years old, have an ECOG performance status ≤2, and be diagnosed with clear cell and/or sarcomatoid histology. The study is open to all IMDC risk groups. Patients must have measurable disease by RECIST 1.1 and no prior systemic therapy for metastatic disease. The study follows a 3+3 dose-escalation design with three planned dose levels for CBM588 (4 × 10 8 CFU, 1.2 × 10 9 CFU, and 4 × 10 9 CFU), administered twice daily orally. Nivolumab (3 mg/kg every 3 weeks for four cycles, followed by 480 mg every 4 weeks) and ipilimumab (1 mg/kg every 3 weeks for four cycles) are administered intravenously. The primary objective is to assess the safety and tolerability with escalating doses of CBM588 in combination with nivolumab and ipilimumab. Secondary objectives include evaluating changes in the gut microbiome, modulation of immune pathways, alterations to the systemic metabolome, and clinical outcomes such as overall response rate (ORR) and progression-free survival (PFS). Responses are assessed by CT every 12 weeks. Dose level one has been completed without dose-limiting toxicities. Enrollment at dose level two began in October 2024. Clinical trial information: NCT06399419 .

Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial

Journal of Clinical Oncology Teresa Macarulla, Zhenggang Ren, Hong Jae Chon et al. Feb 10, 2025 DOI: 10.1200/jco.24.00337

PURPOSE Biliary tract cancers (BTCs) harbor an immunosuppressed tumor microenvironment and respond poorly to PD-1/PD-L1 inhibitors. Bevacizumab (anti–vascular endothelial growth factor) plus chemotherapy can promote anticancer immunity, augmenting response to PD-L1 inhibition. PATIENTS AND METHODS This randomized, double-blind, proof-of-concept phase II study enrolled patients (n = 162) with previously untreated advanced BTC (IMbrave151; ClinicalTrials.gov identifier: NCT04677504 ). Patients were randomly assigned 1:1 to receive cycles of atezolizumab (1,200 mg) plus bevacizumab (15 mg/kg) or atezolizumab plus placebo once every 3 weeks until disease progression or unacceptable toxicity. All patients received cisplatin (25 mg/m 2 ) plus gemcitabine (1,000 mg/m 2 ; cisplatin plus gemcitabine [CisGem]) on days 1 and 8 once every 3 weeks for up to eight cycles. Stratification of patients was by disease status, geographic region, and primary tumor location. The primary end point was progression-free survival (PFS). No formal hypothesis testing was performed. Exploratory correlative biomarker analysis was undertaken using transcriptome analysis (n = 95) and mutation profiling (n = 102) on baseline tumor samples. RESULTS Between February and September 2021, 162 patients were enrolled. Median PFS was 8.3 months in the bevacizumab arm and 7.9 months in the placebo arm (stratified hazard ratio [HR], 0.67 [95% CI, 0.46 to 0.95]). Median overall survival (OS) was 14.9 and 14.6 months in the bevacizumab and placebo arms, respectively (stratified HR, 0.97 [95% CI, 0.64 to 1.47]). The incidence of grade 3 or 4 adverse events was 74% in both arms. High VEGFA gene expression was associated with improved PFS (HR, 0.44 [95% CI, 0.23 to 0.83]) in the bevacizumab arm versus placebo. CONCLUSION In unselected patients with advanced BTC, adding bevacizumab to atezolizumab plus CisGem modestly improves PFS but not OS. High VEGFA gene expression may represent a predictive biomarker of benefit from atezolizumab/bevacizumab, warranting further investigation.

Datopotamab deruxtecan (Dato-DXd) in locally advanced/metastatic urothelial cancer: Updated results from the phase 1 TROPIONPanTumor01 study.

Journal of Clinical Oncology Funda Meric-Bernstam, Omar Alhalabi, Aaron Lisberg et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.663

663 Background: Dato-DXd is a TROP2-directed antibody-drug conjugate under investigation in various solid tumor types. We report updated results in patients (pts) with locally advanced/metastatic urothelial cancer (la/m UC) from the ongoing phase 1 TROPION-PanTumor01 study (NCT03401385). Methods: Pts with unresectable la/m UC (stage III/IV) treated with ≥1 prior line of therapy, including an immune checkpoint inhibitor, received Dato-DXd 6 mg/kg Q3W. Primary study objectives were safety and tolerability. Secondary endpoints were objective response rate (ORR), duration of response (DOR), and progression-free survival (PFS) per RECIST 1.1 by blinded independent central review (BICR). Results: At data cutoff (April 22, 2024), 40 pts had received Dato-DXd; 8 (20%) were receiving ongoing treatment. Median follow-up was 10.0 (range 5–28) months (mo). Pts were heavily pretreated: 24 (60%) had received ≥3 prior regimens in the locally advanced/metastatic setting, 36 (90%) received prior platinum chemotherapy, and 33 (83%) received prior enfortumab vedotin. Confirmed ORR by investigator was 27.5% (95% CI, 14.6–43.9), including 11 partial responses (PR). Confirmed ORR by BICR was 25.0% (95% CI, 12.7–41.2), including 1 complete response (CR) and 9 PR (Table). Median DOR was not reached (95% CI, 2.6–not evaluable [NE]); 76.2% (95% CI, 33.2–93.5) of responders had ongoing responses at 6 mo. Median PFS by BICR was 6.9 mo (95% confidence interval [CI], 2.9–NE). Treatment-emergent adverse events (TEAEs) occurring in &gt;20% of pts (any grade; grade ≥3) were stomatitis (53%; 5%), nausea (38%; 3%), decreased appetite (30%; 3%), and fatigue (28%; 0%). Grade ≥3 TEAEs occurred in 55% of pts. TEAEs associated with treatment discontinuation, dose reduction, and dose interruption occurred in 8%, 20%, and 35% of pts, respectively. No serious treatment-related AEs or treatment-related grade 4 or 5 AEs were reported. Two pts (5%) had adjudicated drug-related interstitial lung disease/pneumonitis (grade 2 and 3). Conclusions: In heavily pretreated pts with la/m UC, Dato-DXd demonstrated encouraging antitumor activity with a manageable safety profile. Dato-DXd is being evaluated in pts with urothelial cancer in the phase 1/2 TROPION-PanTumor02 (NCT05460273) and the phase 2 TROPION-PanTumor03 (NCT05489211) studies. Clinical trial information: NCT03401385 . Efficacy by BICR. Response All patients N=40 Confirmed ORR, n (%) [95% CI] 10 (25.0) [12.7–41.2] CR 1 (2.5) PR 9 (22.5) SD 20 (50.0) Non-CR/non-PD 1 (2.5) PD 5 (12.5) NE 4 (10.0) DOR at 6 mo, % [95% CI] 76.2 [33.2–93.5] Median PFS, mo [95% CI] 6.9 [2.9–NE] BICR, blinded independent central review; CI, confidence interval; CR, complete response; DOR, duration of response; mo, months; NE, not evaluable; ORR, objective response rate; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease.

Asymmetric small-molecule acceptor enables suppressed electron-vibration coupling and minimized driving force for organic solar cells

Nature Communications Jing Guo, Shucheng Qin, Jinyuan Zhang et al. Feb 10, 2025 DOI: 10.1038/s41467-025-56799-6

Abstract Minimizing the energy loss, particularly the non-radiative energy loss (ΔE nr), without sacrificing the charge collection efficiency, is the key to further improve the photovoltaic performance of organic solar cells (OSCs). Herein, we proposed an asymmetric molecular design strategy, via developing alkyl/thienyl hybrid side chain based asymmetric small molecule acceptors (SMAs) BTP-C11-TBO and BTP-BO-TBO, to manipulate the intermolecular interactions to realize enhanced luminescence efficiency and reduced energy loss. Theoretical and experimental results indicate that compared to the three symmetric SMAs BTP-DC11, BTP-DTBO and BTP-DBO, the asymmetric SMAs BTP-C11-TBO and BTP-BO-TBO exhibit repressed electron-vibration coupling and reduced ΔE nr. Moreover, the asymmetric nature of BTP-BO-TBO allows the formation of multiple D:A interfacial conformations and interfacial energies, which have made the charge-transfer state energies closer to that of the strongly absorbing (and emitting) local-exciton state, thus gaining the low ΔE nr while maintaining efficient exciton dissociation. Consequently, the PM6:BTP-BO-TBO-based OSCs achieve a higher power conversion efficiency of 19.76%, with a high open circuit voltage of 0.913 V and an efficient fill factor of 81.17%, profiting from the more improved and balanced charge mobility and longer carrier lifetime. This work provides molecular design ideas to suppress nonradiative decay and paves the way to obtain high-performance OSCs.

Evaluating neoadjuvant intravesical mitomycin C in NMIBC: A phase III randomized clinical trial.

Journal of Clinical Oncology Roberto Contieri, Alberto Saita, Marco Paciotti et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.803

803 Background: The primary treatment for non-muscle invasive bladder cancer (NMIBC) is transurethral resection (TUR), often followed by adjuvant intravesical therapies. Given the variable response to intravesical therapy, enhancing its efficacy is critical to reducing recurrence and progression to MIBC. Recent studies have shown that MMC induces immunogenic cell death, suggesting its potential in enhancing the effectiveness of other intravesical therapies, such as BCG, activating acquired immunity. This study aimed to evaluate the safety and efficacy of neoadjuvant MMC in patients with NMIBC. Methods: This is a prospective, phase III randomized clinical trial in patients with primary or recurrent BC who had not received intravesical therapy between May 2022 and June 2024 (EudraCT 2021-003751-42; ICH-013). Patients were randomized 1:1 to either the neoadjuvant MMC arm (neoA) or the standard treatment arm (StA). In the two weeks preceding the scheduled TURBT (day 0), patients in the neoA arm received intravesical MMC (40 mg/40 ml) on days -14 and -7, along with cystoscopy and cold-cup biopsy on day -14. Clinical decisions regarding adjuvant therapy and follow-up (FU) schedules in both groups were based on the tumor histology according the European Association of Urology (EAU) guidelines. The primary endpoint was to evaluate the safety, and efficacy of neoadjuvant MMC in reducing the recurrence rate of BC. Patients with MIBC or pT0 were excluded from survival analyses. Results: A total of 63 patients were included: 31 (49%) in the StA group and 32 (51%) in the neoA group. The groups were homogeneous in clinical and pathological characteristics.In the neoA group, 8 adverse events (AEs) were reported in 5 patients (14%), all mild (Grade 1 and 2). Following TUR, 26 AEs grade 1 and 2 were observed in 16 (50%) patients in the StA group, and 24 AEs in 14 (45%) patients in the neoA group, with no significant differences between the groups (p=0.6).In the neoA group, 16 patients had TaLG, 9 had TaHG, 3 had T1HG, 1 had CIS, and 2 had benign findings. No complete tumor ablation occurred, with only 2 cases showing reduced tumor size. In the StA group, 17 had TaLG, 6 had TaHG, 5 had T1HG, and 3 had T2 tumors. After a median FU of 14.5 months, 5 patients in the StA group and 4 in the neoA group recurred. Only one patient, in the neoA group, progressed to MIBC. The 12-month recurrence-free survival (RFS) was 91% (95% CI: 68-98) in the StA group and 84% (95% CI: 62-94) in the neoA group, with no statistically significant difference between the two groups (log-rank test p=0.8). Conclusions: Neoadjuvant MMC showed a favorable safety and tolerability profile. Although no significant RFS difference was found between the neoA and standard arms, a larger cohort and longer FU are needed for definitive conclusions on MMC's oncological efficacy. The upcoming analysis of the adjuvant BCG subgroup will further clarify MMC's role in enhancing BCG efficacy.

Darolutamide plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC) by disease volume: Subgroup analysis of the phase 3 ARANOTE trial.

Journal of Clinical Oncology Fred Saad, Neal D. Shore, Egils Vjaters et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.151

151 Background: Darolutamide (DARO) plus ADT significantly reduced the risk of radiological progression or death by 46% (HR 0.54; 95% CI: 0.41–0.71; P &lt;0.0001) versus placebo (PBO) plus ADT in patients with mHSPC in the ARANOTE trial. The incidence of treatment-emergent adverse events (TEAEs) was low and similar between arms, with fewer patients discontinuing study drug due to TEAEs in the DARO vs PBO arm (6.1% vs 9.0%). Here, we report the efficacy and safety by disease volume in both arms of ARANOTE. Methods: Patients with mHSPC were randomized 2:1 to receive DARO 600 mg twice daily + ADT or PBO + ADT. High-volume (HV) disease was defined by the presence of visceral metastases and/or ≥4 bone lesions with ≥1 beyond the vertebral bodies and pelvis (CHAARTED criteria). The primary endpoint was radiological progression-free survival (rPFS). Secondary endpoints included time to metastatic castration-resistant prostate cancer (mCRPC), time to prostate-specific antigen (PSA) progression, and safety. Results: Of the 669 patients included in the full analysis set, 472 (71%; DARO n=315; PBO n=157) had HV disease and 197 (29%; DARO n=131; PBO n=66) had low-volume (LV) disease. Baseline demographics and patient characteristics were generally balanced between the treatment arms in HV and LV subgroups. Patients with LV disease had better prognostic factors (eg, a higher proportion of patients with ECOG PS 0, Gleason &lt;8, having received prior local therapy, and lower baseline median PSA levels). DARO + ADT improved rPFS vs PBO + ADT in both HV and LV subgroups. In the LV subgroup, DARO + ADT reduced the risk of radiological progression or death by 70% (HR 0.30; 95% CI: 0.15–0.60) with median rPFS not reached in either group. In the HV subgroup, DARO + ADT reduced the risk of radiological progression or death by 40% (HR 0.60; 95% CI: 0.44–0.80) with median rPFS of 30.2 months with DARO vs 19.2 months with PBO. For the secondary endpoints, DARO delayed time to CRPC (HV: HR 0.46; 95% CI: 0.36–0.60; LV: HR 0.21; 95% CI: 0.12–0.37) and time to PSA progression (HV: HR 0.34; 95% CI: 0.25–0.46; LV: HR 0.19; 95% CI: 0.10–0.37) and a higher proportion achieved PSA &lt;0.2 ng/mL with DARO vs PBO (HV: 54.6% vs 15.5%; LV: 82.6% vs 25.4%) in HV and LV subgroups. Incidences of TEAEs were low and similar between treatment groups across the HV and LV subgroups and consistent with the overall population. Lower rates of fatigue and treatment discontinuations due to TEAEs with DARO vs PBO were observed in the LV subgroup: 2.3% vs. 13.8% and 3.1% v 10.8%, respectively. Conclusions: Efficacy outcomes with DARO + ADT in patients with mHSPC were improved vs PBO + ADT regardless of disease volume. DARO + ADT was well-tolerated in both volume subgroups, consistent with the overall population. Patients with LV mHSPC had marked treatment efficacy with minimal treatment burden. Clinical trial information: NCT04736199 .

Closing the Gap: Evaluating Medicare's Low-Income Subsidy Support for Optimal Cancer Care

Journal of Clinical Oncology S.M. Qasim Hussaini, Gabrielle B. Rocque Feb 10, 2025 DOI: 10.1200/jco-24-02197

Clinicopathological characteristics and prognosis of metastatic non-clear cell renal cell carcinoma.

Journal of Clinical Oncology Jie Wu, Hong-Lei Cui, Hongzhe Shi et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.504

504 Background: Non-clear cell renal cell carcinoma (nccRCC) is a clinicopathological heterogeneous disease that comprises a complex mixture of different pathology subtypes, accounting for approximately 20% of all RCC cases. Due to its heterogeneity and rarity, standard treatment strategy for metastatic nccRCC remain poorly defined. Methods: We conducted retrospective analysis of 105 metastatic nccRCC patients at our center from June 2010 to April 2022. Demographic, clinicopathological, and systemic therapy data were collected. The data of 872 metastatic ccRCC patients were also collected for comparison.The end points included progression-free survival (PFS) and overall survival (OS). Results: Among 105 metastatic nccRCC patients, the most prevalent histology was papillary RCC (pRCC, 39.0%). The second most common histological type was translocation RCC (tRCC, 29.5%), followed by unclassified RCC (24.8%). The median age of metastatic nccRCC patients was 50 years old. 68.6% patients had advanced primary tumor stage of T3/4, and 48.6% patients had regional lymph node metastasis. The most common distant metastasis site was lung metastasis (52.4%), followed by bone metastasis (33.3%), and 21.0% patients had liver metastasis. The proportion of the favorable, intermediate, and poor IMDC risk group were 19.0%, 54.3%, and 26.7%, respectively. Among metastatic nccRCC patients, 26 received first-line IO-TKI therapy, 79 received first-line TKI monotherapy therapy. During the median follow-up of 22.2 months, there was no statistical significance between the prognosis of IO-TKI and TKI monotherapy group (PFS: 10.9 months vs. 8.6 months, P = 0.23; OS: 23.3 months vs. 24.0 months, P = 0.39). The PFS of tRCC was significantly longer than pRCC and unclassified RCC (P<0.001). According to the Cox regression model, unclassified RCC pathology (HR=2.027,P=0.023) and poor IMDC risk group (HR=2.285,P=0.011) were identified as the independent risk factors for PFS. Poor IMDC risk group was also identified as the independent risk factors for OS (HR=2.638,P=0.007). Compared to metastatic ccRCC, the metastatic nccRCC patients were younger, with more advanced T and N stage, having a higher proportion for liver metastasis. The outcome of metastatic nccRCC was also poorer than metastatic ccRCC patients (P<0.001), with a median OS of 24.0 months and 38.0 months, respectively. Conclusions: Compared to metastatic ccRCC, the prognosis of the patients with metastatic nccRCC was poorer, and the metastatic nccRCC patients were younger, with more advanced T and N stage, having a higher proportion for liver metastasis. Unclassified RCC pathology and poor IMDC risk group were the independent risk factors for poor prognosis. For metastatic nccRCC, the efficacy of IO-TKI was not superior than TKI monotherapy.Therefore, it is of great significance to investigate novel therapeutic targets for metastatic nccRCC.

A fire deficit persists across diverse North American forests despite recent increases in area burned

Nature Communications Sean A. Parks, Christopher H. Guiterman, Ellis Q. Margolis et al. Feb 10, 2025 DOI: 10.1038/s41467-025-56333-8

The feasibility of tumor-infiltrating lymphocyte expansion in non-clear cell renal cell carcinoma.

Journal of Clinical Oncology Christopher Guske, Marine Potez, Justin Miller et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.580

580 Background: The treatment landscape for non-clear cell renal cell carcinoma (nccRCC) lacks personalized therapeutic options. Although adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TILs) has been explored in the treatment of other solid tumors, its potential feasibility and role in nccRCC remains unclear. This study aims to evaluate the feasibility of TIL expansion in nccRCC tumors. Methods: In this IRB-approved study conducted at Moffitt Cancer Center, tumor fragments collected from patients with nccRCC were cultured for 4 weeks in media supplemented with high-dose IL-2 (6000 IU/mL). After the 4-week period, assessments were made of TIL expansion, TIL phenotype, and reactivity to autologous tumor, measured by IFNγ secretion. The percent of T-cell phenotypes among expanded TILs were compared using a paired Student's t-test for normally distributed data and a Wilcoxon signed-rank test for non-normally distributed data. Differences in TIL measures by histologic subtype and TNM staging were analyzed using Kruskal-Wallis testing, while tumor size and patient clinicodemographic data were evaluated with standard linear regression. Results: A total of 16 patients underwent nephrectomy with curative intent for high risk, localized nccRCC. Most patients were male (68.8%) with a median age at time of surgery of 60.3 years (Interquartile Range [IQR]: 50.4-63.9). Histologically, 9 tumors were classified as papillary type 1, two as papillary type 2, one as chromophobe, one as Xp11.2 translocation, and three as unclassified. TILs were successfully grown in all 16 samples, with an average of 47.3% (range: 6.25-100.0) of fragments successfully expanded. The average TIL yield per fragment was 1.24 x 10 7 cells (range: 1.60 x 10 6 – 2.75 x 10 7 ). Reactivity of TILs to autologous tumors was observed in 81.25% of samples. Across each TIL measure, no differences were noted among nccRCC histology subtypes, TNM status, or tumor size. A histologic breakdown of TIL and phenotypic data is provided in the table. Conclusions: In this study, all 16 nccRCC tumor fragments expanded TILs with viable reactivity and marked predominance of T-cells. These results suggest the novel potential for TIL-based therapy in nccRCC histologic subtypes and warrant further investigation. nccRCC TIL expansion measures and phenotype breakdown. Primarily CD3 + T-cells expanded (p=0.01), with a higher proportion of CD4 + T-cells than CD8 + T-cells (p=0.004). Measure, mean ± SD Papillary nccRCC (n=11) Non-Papillary nccRCC (n=5) % Fragment Expanded 54.8 ± 26.7 29.3 ± 19.8 Total TIL Per Fragment 1.2 x 10 7 ± 8.2 x 10 6 1.4 x 10 7 ± 1.0 x 10 7 % Reactive Fragments 65.2 ± 26.8 43.0 ± 46.2 % CD56 + of TIL Expansion 14.1 ± 26.2 9.8 ± 4.6 % CD3 + of TIL Expansion 80.7 ± 26.3 88.5 ± 3.4 % CD4 + of TIL Expansion 50.3 ± 22.6 66.9 ± 18.1 % CD8 + of TIL Expansion 22.5 ± 17.5 12.0 ± 10.2

Real-world treatment patterns and outcomes in advanced prostate cancer: A cohort study using the prostate cancer disease observation (PRECISION) data platform.

Journal of Clinical Oncology Elisabeth I. Heath, Alton Oliver Sartor, Neal D. Shore et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.59

59 Background: There are several real-world data sources for prostate cancer (PC), each with its own limitations; the most notable limitation is an incomplete picture of the multidisciplinary clinical management of PC. The PRECISION data platform, the largest, most comprehensive, and continually updated real-world evidence source on patients with advanced PC to date, tries to address this limitation and shed light on PC management in both urology and oncology practices in both academic and community settings in the US. The platform includes a wide variety of PC-specific data variables among patients with metastatic hormone-sensitive PC (mHSPC) and metastatic castration-resistant PC (mCRPC) treated across the US. This study aims to provide an overview of the characteristics, treatment patterns, and clinical outcomes among patients with mHSPC and mCRPC included in PRECISION to date. Methods: A retrospective cohort study that included patients with a diagnosis of mHSPC or mCRPC (index date) in PRECISION between 2018 and 2024 (cohorts could overlap). For each cohort, patient characteristics and treatment patterns were evaluated descriptively. Results: The PRECISION platform currently includes 72,855 and 33,538 patients with mHSPC and mCRPC, respectively. Among the mHSPC cohort, the mean ± standard deviation (SD) age was 74.5±9.4 years; 67% and 33% were treated at oncology and urology centers, respectively; 40% and 60% were from academic and community settings, respectively. The average ± SD time from mHSPC to mCRPC was 11.2±11.7 months. Overall, 77.6% of patients were treated with androgen-deprivation therapy (ADT), of whom 64.7% had ADT combined with androgen receptor pathway inhibitors (ARPIs) including abiraterone acetate, enzalutamide, and apalutamide. Among the mCRPC cohort, the mean ± SD age was 74.1±9.3 years; similar treatment setting patterns as mHSPC were observed. Overall, 74.6% initiated a first-line (1L) therapy on/after mCRPC diagnosis; 52.1% had 1L ARPIs, 16.2% 1L immunotherapy, and 4.6% 1L taxane chemotherapy. In addition, 2.2% of patients received the recently US FDA-approved therapy, lutetium-177 vipivotide tetraxetan, at some point during their mCRPC disease duration. Conclusions: This analysis provides key insights into the patients included in the PRECISION data platform. This multidisciplinary dataset provides a 70/30 split between oncology and urology centers, and a 40/60 split between academic and community settings. The observed clinical profile, treatment patterns, and outcomes comprise the most comprehensive representation of current treatment practice in the US. Future analyses of clinical outcomes with existing and novel therapies could contribute significantly to our understanding of opportunities to improve the treatment of patients with mHSPC and mCRPC in the US.

Treatment patterns and survival outcomes in metastatic castration-resistant prostate cancer in the Brazilian population: LACOG 1818.

Journal of Clinical Oncology Fernando Cotait Maluf, Suelen Patrícia dos Santos Martins, Deusdedit Cortez Vieira Silva Neto et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.27

27 Background: Prostate cancer is the second leading cause of cancer death in men worldwide. In Brazil, 75% of patients (pts) rely on the public healthcare system, where access to novel therapies is limited. This disparity may lead to significant differences in survival outcomes. The LACOG 1818 study aims to address this gap by evaluating survival outcomes and treatment patterns among Brazilian pts diagnosed with metastatic castration resistant prostate cancer (mCRPC) in different healthcare settings (public versus private). Methods: LACOG 1818 is a retrospective cohort that included Brazilian pts from 18 research sites diagnosed with mCRPC between Jan 2014 and Dec 2017. Data on pts demographics, clinicopathological features, treatment patterns, and overall survival (OS) were collected from medical records. The primary endpoint was cause-specific survival (CSS) estimated by Kaplan-Meier method. Comparisons between groups (public vs. private healthcare) were assessed by chi-square and the log-rank tests. Results: From Jan 2020 to Jan 2022, 582 eligible pts were included. The median age was 49 (26-53) years, 259 (45%) were white and 85 (15%) were black/brown. Most had bone metastases (n=499, 86%), followed by non-regional lymph-nodes (n=239, 41%). A total of 323 (55%) pts had public and 259 (45%) had private health coverage. The main modality of castration was biochemical castration (n=442, 76% [public 60% vs. private 96%; p&lt;0.0001]), followed by bilateral orchiectomy (n=140, 24% [public 40% vs. private 4%; p&lt;0.0001]). 499 pts had available data on systemic treatment for mCRPC: 473 (95%) received first line; 247 (49%) second line; and 147 (29%) ≥ 3 lines. 378 (65%) pts received a bone protector agent (63% in public vs. 68% in private; p &lt;0.001). At median follow-up of 59 months (95% CI 54.3-62.1), median OS was 57.1 months (95% CI 47.0-65.2) in overall sample; 44.8 months (95% CI 36.0-57.1) in public versus 65.7 months (95% CI 59.8-79.1) in private (HR 1.4 [95%IC 1.1-1.8] p=0.0051). The median CSS was 73.8 months (95% CI 55.1.-NR) in public versus 102.4 months (95% CI 83.4-102.4) in private (HR 1.9 [95%IC 1.4-2.6] p&lt;0.0001). Conclusions: LACOG 1818 study demonstrated significant disparities in treatment patterns and survival outcomes between public and private settings for Brazilian pts with mCRPC. Pts with private coverage had longer OS and CSS. These findings underscore the need for improved access to novel therapies and comprehensive cancer care in Brazil's public healthcare system to reduce survival disparities. Clinical trial information: NCT04962919 . Private Public P First-line N=221 N= 251 &lt;0.0001 ARPI 132 (60%) 18 (7%) Antiandrogen 30 (13%) 127(51%) Chemotherapy 59 (27%) 106 (42%) Second-line N=132 N=110 &lt;0.0001 ARPI 75 (57%) 25 (23%) Antiandrogen 5 (4%) 22 (20%) Chemotherapy 52 (39%) 63 (57%) ARPI= Antiandrogen receptor pathways inhibitor. Antiandrogen= bicalutamide, flutamide, cyproterone and DES.

Resonant inelastic X-ray scattering tools to count 5 f electrons of actinides and probe bond covalency

Nature Communications Bianca Schacherl, Michelangelo Tagliavini, Hanna Kaufmann-Heimeshoff et al. Feb 10, 2025 DOI: 10.1038/s41467-024-54574-7

Abstract The actinides possess a complex electronic structure, making their chemical and physical properties among the least understood in the periodic table. Advanced spectroscopic tools, able to obtain deep insights into the electronic structure and binding properties of the actinides, are highly desirable. Here, we introduce two sensitive spectroscopic tools: one determines the number of localized 5 f electrons on an actinide atom, and another assesses the covalent character of actinide-ligand bonding. Both tools are based on the multiplet structure present in actinide M 4 edge core-to-core resonant inelastic X-ray scattering (CC-RIXS) maps. The spectral intensity of different many-body final-state multiplets directly depends on the local many-electron ground-state symmetry including the local 5  f spin configuration. By comparing U M 4 edge CC-RIXS data for 21 U, Np, Pu and Am compounds, we demonstrate the ability to compare the number of localized 5  f electrons and bond covalency across the actinide series.

A prognostic biomarker panel for chromophobe renal cell carcinoma using immunohistochemistry.

Journal of Clinical Oncology Elizabeth Ellis, Ashley Li, Phillip Rappold et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.596

596 Background: The American Cancer Society estimates 14,390 deaths from kidney cancer in 2024 Chromophobe renal cell carcinoma (chRCC) is the third most common subtype of kidney cancer, and 5-10% of patients with chRCC develop metastatic disease. Being able to prognosticate which tumors are aggressive vs. indolent is a significant unmet need. Methods: All partial and radical nephrectomies performed at our institution between 2012-2018 were queried. Cases stage pT1a-pT3a N0M0 at the time of surgery with a minimum of three-year follow up were included. Cases were evaluated for recurrence after surgery. chRCC tissue microarrays (TMA) were constructed from formalin-fixed paraffin-embedded surgical specimens with five 2 mm cores obtained from each tumor. Biomarker choice was hypothesis driven based on publicly available TCGA data. Immunohistochemistry (IHC) was performed for each antibody (Ab) of interest per protocol, with appropriate positive and negative controls. A blinded genitourinary pathologist reviewed the slides and designated an average Immunoreactive Score for all 5 punches for each Ab. Log rank test was used to compare expression levels of recurrent disease to non-recurrent disease based on high and low biomarker expression. Survival analysis for 0-3 positive markers was performed using Log-rank test. Results: Forty-six patients were included in the TMA. Six had recurrent disease: two developed metastasis and four had local recurrences. Two recurrences were from pT1a primaries, two were from pT1b primaries, and two were from pT3a primaries. One metastasis developed from a pT1b primary and one from a pT3a primary. Median length of follow up was 70.5 months, median age at surgery was 54.5 years, median time to recurrence was 32 months, and median mass size was 4.1 cm. High expression of glucose transporter 1 (GLUT1; hazard ratio (HR) = 33.6, p = 0.02) and Claudin-7 (HR = 6.1, p = 0.02) and low expression of platelet derived growth factor receptor (PDGFR; HR = 7.9, p = 0.005) relative to the median was associated with metastatic disease. Recurrences also tended to have high expression of cluster of differentiation 10 (CD10). When markers were combined as a panel, having two to three positive markers was associated with decreased recurrence free survival (RFS) on univariate analysis. Median RFS was 23 months vs. 92 months for three vs. two positive markers, respectively (p &lt; 0.0001). Conclusions: High expression of GLUT1, important in glycolysis, and the epithelial mesenchymal transitional markers CD10 and Claudin-7 and low PDGFR is a protein expression signature that may signal chRCC capable of recurrent or metastatic disease. This provides post-translational insight to proteins that may be important for chRCC invasion and metastasis. Biomarker analysis using IHC is readily and widely available for use. External validation in a larger cohort is currently underway.

Circulating tumor cell (CTC) expression patterns of cell surface targets in metastatic prostate cancer.

Journal of Clinical Oncology Kendra D. Marr, Jamie M Sperger, Amy K Taylor et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.232

232 Background: Resistance to first-line Androgen Receptor Pathway Inhibitors (ARPI) in metastatic prostate cancer (mPC) is universal and can be driven by androgen receptor (AR) alterations driving constitutive AR signaling, or lineage state transitions that bypass AR and culminate in small cell/neuroendocrine PC (NEPC). Recent advances in cell surface targeted therapies, including radioligand therapies and antibody drug conjugates show promise for treatment of metastatic castrate-resistant prostate cancer (mCRPC). Circulating tumor cells (CTCs) are a minimally-invasive source of tumor material to track these known and novel targets for therapeutic development. We report differential expression of cell surface targets using the largest CTC RNA sequencing cohort of patients with mPC across lineage states and clinical outcomes. Methods: We isolated CTCs using automated microfluidic technology on a 273-sample cohort from patients with histologically confirmed mPC. CTCs purified via anti-EpCAM conjugated magnetic beads were analyzed via RNA-seq. We examined CTC gene expression of cell surface targets, including PSMA, TROP2, B7H3, DLL3, stratified by: disease category (metastatic castration sensitive PC [mCSPC], mCRPC or NEPC), metastatic site (bone +/- lymph nodes, liver, other visceral), and prior ARPI treatment. Results: CTCs from patient with mCRPC showed high expression of canonical adenocarcinoma cell surface targets STEAP1 , KLK2 and FOLH1 (PSMA) and epithelial TACSTD2 (TROP2), intermediate tumor immune checkpoint cell surface protein CD276 (B7H3), and low expression of NEPC targets DLL3 and SSTR2 . CTCs from NEPC patients, as expected, demonstrated lower expression of most adenocarcinoma targets and a trend towards higher DLL3 and SSTR2 and associates with worse OS regardless of disease site in multivariate analysis (HR 4.76 [1.09-8.44], p=0.011). CTCs from patients with mCSPC had highest TACSTD2 (p=0.0076) and a trend towards lower DLL3 expression. When comparing metastatic sites, CTCs from non-NEPC mCRPC patients with liver metastases had significantly higher expression of DLL3 (p=0.012) compared to bone or non-liver visceral metastases and can be detected in high-risk adenocarcinomas though expression is heterogeneous. Conversely, CTCs from mCRPC with liver metastases had lower TACSTD2 expression (p=0.039). Prior ARPI therapy associated with lower TACSTD2 (p=0.025) and a trend toward higher DLL3 in patients with early evidence of lineage transition. Conclusions: We report differential cell surface target expression across lineage states and disease sites using novel CTC RNA-seq and single CTC phenotyping. Altered target expression was observed in PC lineage transitions. These findings have implications for treatment response towards surface targeted therapies, and future studies will utilize these biomarkers to explore mechanisms of response and resistance.